Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (199)	7/13/2001 4:35:50 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1022

Not a dumb question at all. Lots of us study MEDI-507. The mechanism is not defined. However, in vitro studies indicate that the antibody can induce apoptosis in T cells that have otherwise been activated by antigen. That's why I always wanted to see the minimum dose at which the antibody could be effective in a human (the epitope is not expressed on species which are relevant for preclinical in vivo testing). The antibody appears to effect a significant clinical response at approximately 2 mg/human recipient. Does that mean that the "agonist" (induction of apoptosis) function is validated? Don't know, but it's looking good, IMO.